Our study supports the hypothesis that enhancing ABCA1-mediated efflux in RPE cells, e.g., by using an LXR agonist, could be a feasible treatment option to normalize efflux and intracellular accumulation of lipids in AMD patients. Here, ABCA1 is linked to age-related macular degeneration.